Researchers from Harvard University and the University of Illinois at Chicago have created an antibiotic that may provide a fresh tool in the fight against drug-resistant bacteria and the illnesses they cause.
According to Science, the antibiotic cresomycin efficiently reduces pathogenic microorganisms that have developed resistance to a variety of frequently administered antimicrobial medications.
The promising new antibiotic is the result of a long-term collaboration between Yury Polikanov’s laboratory at UIC, an associate professor of biological sciences, and colleagues at Harvard. Harvard researchers use the vital insights into cellular functions and structure that the UIC scientists provide to assist design and synthesis of novel medications.
In developing the new antibiotic, the group focused on how many antibiotics interact with a common cellular target – the ribosome – and how drug-resistant bacteria modify their ribosomes to defend themselves.
More than half of all antibiotics inhibit the growth of pathogenic bacteria by interfering with their protein biosynthesis – a complex process catalyzed by the ribosome, which is akin to “a 3D printer that makes all the proteins in a cell,” Polikanov said. Antibiotics bind to bacterial ribosomes and disrupt this protein-manufacturing process, causing bacterial invaders to die.
But many bacterial species evolved simple defences against this attack. In one defence, they interfere with antibiotic activity by adding a single methyl group of one carbon and three hydrogen atoms to their ribosomes.
Scientists speculated that this defence was simply bacteria physically blocking the site where drugs bind to the ribosome, “like putting a push pin on a chair,” Polikanov said. But the researchers found a more complicated story, as they described in a paper published last month in Nature Chemical Biology.
By using a method called X-ray crystallography to visualize drug-resistant ribosomes with nearly atomic precision, they discovered two defensive tactics. The methyl group, they found, physically blocks the binding site, but it also changes the shape of the ribosome’s inner “guts,” further disrupting antibiotic activity.
Polikanov’s laboratory then used X-ray crystallography to investigate how certain drugs, including one published in Nature by the UIC/Harvard collaboration in 2021, circumvent this common form of bacterial resistance.
“By determining the actual structure of antibiotics interacting with two types of drug-resistant ribosomes, we saw what could not have been predicted by the available structural data or by computer modelling,” Polikanov said.
“It’s always better to see it once than hear about it 1,000 times, and our structures were important for designing this promising new antibiotic and understanding how it manages to escape the most common types of resistance.”
Cresomycin, the new antibiotic, is synthetic. It’s preorganized to avoid the methyl-group interference and attach strongly to ribosomes, disrupting their function. This process involves locking the drug into a shape that is pre-optimized to bind to the ribosome, which helps it get around bacterial defences.
“It simply binds to the ribosomes and acts as if it doesn’t care whether there was this methylation or not,” Polikanov said. “It overcomes several of the most common types of drug resistance easily.”
In animal experiments conducted at Harvard, the drug protected against infections with multidrug-resistant strains of common disease drivers including Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Based on these promising results, the next step is to assess the effectiveness and safety of cresomycin in humans.
But even at this early stage, the process demonstrates the critical role that structural biology plays in designing the next generation of antibiotics and other life-saving medicines, according to Polikanov.
“Without the structures, we would be blind in terms of how these drugs bind and act upon modified drug-resistant ribosomes,” Polikanov said.
“The structures that we determined provided fundamental insight into the molecular mechanisms that allow these drugs to evade the resistance.”
(With inputs from ANI)
